| This is the first study to prospectively investigate drug-induced interstitial lung disease and the value of diverse diagnostic biomarkers to discriminate ILD from alternate diagnoses. |
| Diffusion capacity and the plasma biomarkers YKL-40 and SP-D can differentiate everolimus-induced ILD from alternate causes. |
| A rapid decrease in diffusion capacity could be an indication of severe ILD needing treatment discontinuation. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.